NEW ORLEANS and CHAPEL HILL, N.C., April 4, 2011 /PRNewswire/ —
Cardioxyl Pharmaceuticals, Inc. announced today that it is
presenting two abstracts from studies of its lead clinical
candidate, CXL-1020, at the American College of Cardiology’s (ACC)
60th Annual Scientific Session & Expo in New Orleans,
Louisiana. Preclinical results highlighted in the first abstract
demonstrate CXL-1020’s ability to work independently from other
heart failure therapies, furthering important insights into the
cellular mechanism of action of nitroxyl donors. Clinical results
presented in the second abstract demonstrate, for the first time,
CXL-1020’s safety and tolerability in people who have stable
congestive heart failure (CHF), a good predictor of safety in
people with acute decompensated heart failure (ADHF).
“Today’s research findings provide additional support for the
unique mechanism of CXL-1020 and for its strong safety profile and
tolerability in patients with stable CHF,” said Chris Kroeger,
M.D., President and Chief Executive Officer. “We are
currently enrolling a Phase IIa clinical trial to further define
safety, tolerability and dosing for CXL-1020 in patients with ADHF,
bringing us closer to making this treatment a reality for the
millions who suffer from this disease.”
Following are the details of the data presented at ACC Poster
Sessions:
CXL-1020, a Novel HNO Donor, Decreases Myocardial Loading and
Enhances Load-Independent Lusitropy and Inotropy via a
Beta–AR/ACE Independent Mechanism. Monday, April 4,
2011; 1:45 p.m. – 4:45 p.m., Ernest N. Morial Convention
Center, Hall F; Poster Board #21
In this preclinical study, Cardioxyl and QTest Labs researchers
compared the hemodynamic profile of CXL-1020 with the vasodilator,
sodium nitroprusside (SNP). The results show that under
conditions of matched reduction of systolic pressure, CXL-1020 and
SNP increased stroke volume without incre
‘/>”/>
